Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$244.28 USD

244.28
1,118,394

+1.81 (0.75%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Neogen's (NEOG) MDS Secures New Contract From USDA FSIS

by Zacks Equity Research

Neogen's (NEOG) MDS gets recognized by the USDA FSIS as the primary method for the detection of Salmonella and Listeria monocytogenes testing for meat, poultry and egg products.

Is Insulet (PODD) Stock an Apt Pick for Your Portfolio Now?

by Zacks Equity Research

The robust performance of Insulet's (PODD) Omnipod 5 raises investors' optimism. However, concerns remain over the macroeconomic impacts and the company's overdependence on a single platform.

Illumina (ILMN) Advances in NGS With DRAGEN v4.3 Launch

by Zacks Equity Research

One of the standout features of Illumina's (ILMN) DRAGEN v4.3 is its machine-learning mosaic model.

Abbott's (ABT) AVEIR DR Leadless Pacemaker System Gains CE Mark

by Zacks Equity Research

Abbott (ABT) receives a CE mark for AVEIR DR, the world's first dual chamber leadless pacemaker system.

Abbott (ABT) Gets FDA Nod for Two Glucose Monitoring Systems

by Zacks Equity Research

Abbott's (ABT) glucose monitoring systems - Lingo and Libre Rio - based on Freestyle Libre technology, receive FDA clearance.

Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes

by Zacks Equity Research

Myriad Genetics (MYGN) continues to enhance its customer targeting, digital marketing and overall operating model to drive commercial leverage in 2024 and beyond.

Charles River (CRL) Partners to Reduce Animal Research Usage

by Zacks Equity Research

Charles River (CRL) announces the development of non-clinical VCG with Sanofi to reduce the use of animals in research.

Zacks.com featured highlights include ResMed, Booz Allen Hamilton, CrediCorp and American Express

by Zacks Equity Research

ResMed, Booz Allen Hamilton, CrediCorp and American Express have been highlighted in this Screen of The Week article.

Align Technology (ALGN) Gains From New Alliances, Global Growth

by Zacks Equity Research

Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America.

Shilpa Mete headshot

4 GARP Stocks to Scoop up for Maximum Returns

by Shilpa Mete

Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RMD, BAH, BAP and AXP are some stocks that hold promise.

Capricor (CAPR) Advances in DMD Therapy With Positive Study Data

by Zacks Equity Research

Capricor (CAPR) anticipates announcing top-line results from the Phase 3 HOPE-3 pivotal trial by the fourth quarter of 2024.

QIAGEN (QGEN) Unveils dPCR Tool, Enhances GeneGlobe Platform

by Zacks Equity Research

QIAGEN (QGEN) launches the digital PCR Assay Design Tool for QIAcuity and expands the customization capabilities of its GeneGlobe research platform.

Here's Why Omnicell (OMCL) Should be in Your Portfolio Now

by Zacks Equity Research

A robust Advanced Services portfolio and strategic restructuring initiatives bode well for Omnicell (OMCL).

Medtronic (MDT) Cardiovascular Business Expands Amid Macro Woes

by Zacks Equity Research

For Hugo surgical robot, Medtronic (MDT) is scaling manufacturing production, expanding regulatory approvals and ramping up installations to see continued progress internationally.

ICON (ICRL) Gains From Strategic Acquisitions, Innovation

by Zacks Equity Research

In addition to its focused efforts within the biotech segment, ICON (ICLR) continues to drive forward its leadership in large pharma.

Here's Why Thermo Fisher (TMO) Should be in Your Portfolio

by Zacks Equity Research

Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).

Henry Schein (HSIC) Banks on Global Expansion Amid Macro Issues

by Zacks Equity Research

Within the Dental business, Henry Schein (HSIC) is aiming to deliver customized solutions, leveraging market insights and technological advancements.

Here's Why ResMed (RMD) is a Strong Momentum Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

IDEXX (IDXX) Expands Test Menu for the Catalyst Platform

by Zacks Equity Research

IDEXX's (IDXX) new Catalyst Pancreatic Lipase Test is likely to support veterinarians globally in diagnosing pancreatitis.

QIAGEN's (QGEN) New Launch Expands US Syndromic Testing Menu

by Zacks Equity Research

QIAGEN's (QGEN) new QIAstat-Dx Gastrointestinal Panel 2 offers fast and accurate identification of up to 16 common gastrointestinal pathogens.

Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM).

HealthEquity (HQY) Q1 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2025.

Zimmer Biomet (ZBH) Procedure Recovery Aids Amid Macro Woes

by Zacks Equity Research

Zimmer Biomet (ZBH) continues to record strong procedure volume in 2024 in both the Knees and Hips businesses, banking on an improved market scenario.

Bruker (BRKR) Launches neofleX MALDI-TOF/TOF MSI System

by Zacks Equity Research

Bruker's (BRKR) neofleX is a versatile, high-performance and easy-to-use multiomics MSI system for biopharma, translational and clinical researchers.

Omnicell (OMCL) Gains From New Offerings Amid Cost Woes

by Zacks Equity Research

With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.